Deciphera Pharmaceuticals, LLC
Los Angeles, California
What changed
Phase II trial registered: A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
5d agoTrial registeredJul 13, 2026Source filing (opens the source filing in a new tab)
Momentum
Momentum 77 out of 100, unchanged since the last recompute.
Accelerating: several high-weight events landed recently.
Runway (estimate)
No disclosed raise on file, so there is nothing to model from.
Stage
Phase III
The furthest-along thing in the public record. Not a projection.
Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.
Grant to raise
Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.
- Trial
PHASE3 registered
Dec 13, 2023GIST · ACTIVE_NOT_RECRUITING · sponsor: Deciphera Pharmaceuticals, LLC · A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
ClinicalTrials.gov · NCT05734105 (opens the source filing in a new tab)
- Trial
PHASE1/PHASE2 registered
Sep 28, 2023GIST · RECRUITING · sponsor: Deciphera Pharmaceuticals, LLC · A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
ClinicalTrials.gov · NCT05957367 (opens the source filing in a new tab)
Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources